Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
1/16/2024 | $17.00 → $17.50 | Buy → Neutral | Compass Point | |
11/21/2023 | $17.00 | Neutral | UBS | |
8/30/2023 | $17.50 | Neutral → Buy | Compass Point | |
8/4/2023 | $13.50 → $17.00 | Underperform → Mkt Perform | Keefe Bruyette | |
4/6/2023 | $16.00 | Neutral → Overweight | Piper Sandler | |
3/13/2023 | $14.50 → $10.50 | Mkt Perform → Underperform | Keefe Bruyette | |
7/29/2022 | Outperform → Perform | Oppenheimer | ||
4/22/2022 | $18.00 | Outperform → Mkt Perform | Keefe Bruyette |
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
424B3 - Hercules Capital, Inc. (0001280784) (Filer)
8-K - Hercules Capital, Inc. (0001280784) (Filer)
8-K - NeueHealth, Inc. (0001671284) (Filer)
SC 13D/A - NeueHealth, Inc. (0001671284) (Subject)
SC 13G - Hercules Capital, Inc. (0001280784) (Subject)
SC 13G/A - Hercules Capital, Inc. (0001280784) (Filed by)
Facility adds operational flexibility and provides funding for the recently announced Phase 3 PEAK-1 study for casdatifan. $150 million committed, of which $50 million was drawn at closing and the remaining $100 million available at Arcus's sole discretion. Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported it has obtained a $250 million term loan facility from Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in life sciences and technology-related markets. The additional capital strengthens Arcus's
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Kroll Bond Rating Agency, Inc. ("KBRA") has reaffirmed Hercules' investment grade corporate and credit rating of BBB+. KBRA issued a statement announcing the reaffirmation of the rating and stable outlook, as well as its underlying analysis. "We are very pleased that KBRA has reaffirmed our BBB+ investment grade corporate and credit rating," stated Seth Meyer, chief financial officer of Hercules. "Th
Drove solid Q2 ‘24 results with continued focus on advancing value-driven model and delivering high-quality, consumer-centric care to all populations across the ACA Marketplace, Medicare, and Medicaid Delivered positive Adjusted EBITDA for the second consecutive quarter in 2024; reaffirming Adjusted EBITDA guidance for the full year Positioned for continued strong performance this year and beyond, expecting to reach high end of guidance range for consumers served by year-end NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE:NEUE), the value-driven healthcare company, today reported financial results for its second quarter ended June 30, 2024. "We continued to build momentum
Drove solid Q2 ‘24 results with continued focus on advancing value-driven model and delivering high-quality, consumer-centric care to all populations across the ACA Marketplace, Medicare, and Medicaid Delivered positive Adjusted EBITDA for the second consecutive quarter in 2024; reaffirming Adjusted EBITDA guidance for the full year Positioned for continued strong performance this year and beyond, expecting to reach high end of guidance range for consumers served by year-end NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE:NEUE), the value-driven healthcare company, today reported financial results for its second quarter ended June 30, 2024. "We continued to build momentum
Q2 2024 Total Gross Debt and Equity Commitments of $686.5 Million Record Q2 2024 Total Gross Fundings of $461.5 Million, an Increase of 28.7% Year-over-Year Record Q2 2024 Total Investment Income of $125.0 Million, an Increase of 7.5% Year-over-Year Q2 2024 Net Investment Income "NII" of $82.4 Million, or $0.51 per Share, an Increase of 8.8% Year-over-Year Q2 2024 NII Provides 128% Coverage of the Base Cash Distribution Conservative Balance Sheet Management with Net GAAP Leverage of 93.3% and Net Regulatory Leverage of 83.9% Undistributed Earnings Spillover of $145.0 Million, or $0.89(1) per Ending Shares Outstanding Approximately $4.6 Billion of Assets Under Management, an In
NeueHealth, Inc. ("NeueHealth") (NYSE:NEUE), the value-driven healthcare company, today announced it will report Second Quarter financial results before the financial markets open on Wednesday, August 7, 2024, followed by a conference call at 8:00 AM Eastern Time. To participate via telephone, please pre-register at this link. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including dial-in number, conference number, and personal code that can be used to access the call. A webcast of the earnings call may also be accessed via NeueHealth's Investor Relations page at investors.neuehealth.com. The company suggests part
SAUSALITO, Calif., Nov. 29, 2023 /PRNewswire/ -- Revelation Partners, a healthcare investment firm with over $1.5 billion of capital under management, announced today the addition of Andrew Olson as Partner, Chief Financial Officer and Chief Operating Officer. Mr. Olson has an extensive background in the venture capital and funds management industry. His addition to the team will enhance the firm's technical expertise, support the differentiated investment model, and strengthen the firm's ongoing foundation. As the firm's new Chief Financial Officer and Chief Operating Officer
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Nikos Theodosopoulos was appointed to serve as an independent member of its board of directors, effective September 21, 2023. Mr. Theodosopoulos is an experienced corporate executive and board director with more than 38 years in senior management roles in both the financial services and technology industries. Mr. Theodosopoulos will serve on the Company's Audit Committee. "Nikos' combined experienc
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that DeAnne Aguirre was appointed to serve as an independent member of its board of directors, effective June 23, 2022. Ms. Aguirre is an experienced corporate executive and Board Director with more than 30 years in senior leadership managing large and complex domestic and international business units. Ms. Aguirre will serve on the Nominating and Corporate Governance Committee. "As we continue to expand o
Compass Point downgraded Hercules Capital from Buy to Neutral and set a new price target of $17.50 from $17.00 previously
UBS initiated coverage of Hercules Capital with a rating of Neutral and set a new price target of $17.00
Compass Point upgraded Hercules Capital from Neutral to Buy and set a new price target of $17.50
5 analysts have expressed a variety of opinions on Hercules Capital (NYSE:HTGC) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 4 1 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 3 1 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $20.5, a high estimate of $22.00, and a low estimate of $19.00. Observing a 3.54% increase, the current average has
Piper Sandler analyst Crispin Love maintains Hercules Capital (NYSE:HTGC) with a Overweight and raises the price target from $21.5 to $22.